Market Newsdesk

SAN ANTONIO, April 10, 2025 (GLOBE NEWSWIRE) — Rush Enterprises, Inc., (NASDAQ: RUSHA & RUSHB), which operates the largest network of commercial vehicle dealerships in North America will host a conference call to discuss earnings for the first quarter 2025 on Thursday, May 1, 2025 at 10:00 a.m. Eastern/9:00 a.m. Central. Earnings will be reported after the close of market on Wednesday, April 30, 2025.

The call will be available at http://investor.rushenterprises.com/events.cfm on Thursday, May 1, 2025 at 10:00 a.m. Eastern/9:00 a.m. Central.

Participants may register for the call at:
https://edge.media-server.com/mmc/p/ebf6emci
While not required, it is recommended that you join the event 10 minutes prior to the start.

Attendees who would like to participate in the Q&A portion of the call, please dial one of the following telephone numbers:

For those who cannot listen to the live broadcast, the webcast replay will be available at http://investor.rushenterprises.com/events.cfm.

About Rush Enterprises, Inc.

Rush Enterprises, Inc. is the premier solutions provider to the commercial vehicle industry. The Company owns and operates Rush Truck Centers, the largest network of commercial vehicle dealerships in North America, with more than 150 locations in 22 states and Ontario, Canada, including 125 franchised dealership locations. These vehicle centers, strategically located in high traffic areas on or near major highways throughout the United States and Ontario, Canada, represent truck and bus manufacturers, including Peterbilt, International, Hino, Isuzu, Ford, Dennis Eagle, IC Bus and Blue Bird. They offer an integrated approach to meeting customer needs – from sales of new and used vehicles to aftermarket parts, service and body shop operations plus financing, insurance, leasing and rental. Rush Enterprises’ operations also provide CNG fuel systems (through its investment in Cummins Clean Fuel Technologies, Inc.), telematics products and other vehicle technologies, as well as vehicle up-fitting, chrome accessories and tires. For more information, please visit us at www.rushtruckcenters.comwww.rushenterprises.com and www.rushtruckcentersracing.com, on Twitter @rushtruckcenter and Facebook.com/rushtruckcenters.

Contact:

Rush Enterprises, Inc., San Antonio, Texas
Steve Keller (830) 302-5226

MIAMI, April 10, 2025 (GLOBE NEWSWIRE) — Varonis Systems, Inc. (Nasdaq: VRNS), the leader in data security, announced that it will report its first quarter 2025 financial results following the close of the U.S. financial markets Tuesday, May 6, 2025.

In conjunction with this announcement, Varonis will host a conference call Tuesday, May 6, 2025, at 4:30 p.m. ET to discuss the company’s financial results.

To access this call, dial 877-425-9470 (domestic) or 201-389-0878 (international). The conference ID number is 13752980. A replay of this conference call will be available through May 13, 2025, at 844-512-2921 (domestic) or 412-317-6671 (international). The replay passcode is 13752980.

A live webcast of this conference call will be available on the “Investor Relations” page of the company’s website (https://ir.varonis.com), and the replay will be archived on the website for one year.

Additional Resources

• For more information on Varonis’ solution portfolio, please visit www.varonis.com.
• Visit our blog, and join the conversation on X, LinkedIn and YouTube.

About Varonis

Varonis (Nasdaq: VRNS) is the leader in data security, fighting a different battle than conventional cybersecurity companies. Our cloud-native Data Security Platform continuously discovers and classifies critical data, removes exposures, and detects advanced threats with AI-powered automation.

Thousands of organizations worldwide trust Varonis to defend their data wherever it lives — across SaaS, IaaS, and hybrid cloud environments. Customers use Varonis to automate a wide range of security outcomes, including data security posture management (DSPM), data classification, data access governance (DAG), data detection and response (DDR), data loss prevention (DLP), AI security, and insider risk management.

Varonis protects data first, not last. Learn more at www.varonis.com.

Investor Relations Contact:

Tim Perz
Varonis Systems, Inc.
646-640-2112
[email protected]

News Media Contact:

Rachel Hunt
Varonis Systems, Inc.
877-292-8767 (ext. 1598)
[email protected]

SEATTLE, April 10, 2025 (GLOBE NEWSWIRE) — Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will report financial results for the first quarter 2025 after market close on Thursday, May 1, 2025. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Live audio of the webcast will be available on the “Investors” section of the company website at: www.adaptivebiotech.com. The webcast will be archived and available for replay within 24 hours after the event.

About Adaptive Biotechnologies

Adaptive Biotechnologies (“we” or “our”) is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature’s most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Our proprietary immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed. We apply our platform to partner with biopharmaceutical companies, inform drug development, and develop clinical diagnostics across our two business segments: Minimal Residual Disease (MRD) and Immune Medicine. Our commercial products and clinical pipeline enable the diagnosis, monitoring, and treatment of diseases such as cancer and autoimmune disorders. Our goal is to develop and commercialize immune-driven clinical products tailored to each individual patient.

ADAPTIVE INVESTORS

Karina Calzadilla, Vice President, Investor Relations and FP&A
201-396-1687
[email protected]

ADAPTIVE MEDIA

Erica Jones, Associate Director, Corporate Communications
845-344-7542
[email protected]

DUBLIN, April 10, 2025 (GLOBE NEWSWIRE) — Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced that the Compensation Committee of Avadel’s Board of Directors approved the grant of non-statutory options to nine (9) new employees to purchase 48,400 ordinary shares under Avadel’s 2021 Inducement Plan. The awards were granted as an inducement material to the employee’s acceptance of employment with Avadel in accordance with Nasdaq Listing Rule 5635(c)(4). The options have a ten-year term and vest over four years, with 25% vesting on the one-year anniversary of each new employee’s respective start date and 25% vesting on the second, third, and fourth anniversary thereafter. The options are subject to the terms and conditions of Avadel’s 2021 Inducement Plan approved by the Board of Directors in November 2021 and the terms and conditions of award agreements covering the grants.

About Avadel Pharmaceuticals plc

Avadel Pharmaceuticals plc (Nasdaq: AVDL) is a biopharmaceutical company focused on transforming medicines to transform lives. Our approach includes applying innovative solutions to the development of medications that address the challenges patients face with current treatment options. Avadel’s commercial product, LUMRYZ™, was approved by the U.S. Food & Drug Administration (FDA) as the first and only once-at-bedtime oxybate for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients 7 years and older with narcolepsy. For more information, please visit www.avadel.com. 

Investor Contact:

Austin Murtagh
Precision AQ
[email protected]   
(212) 698-8696

Media Contact:

Lesley Stanley
Real Chemistry
[email protected]
(609) 273-3162